Suboxone generic name
Pro Research Analysisby 
Searched over 200M research papers
Suboxone Generic Name: Buprenorphine/Naloxone
Introduction to Suboxone and Its Generic Formulations
Suboxone, a brand name for the combination of buprenorphine and naloxone, is widely used in the treatment of opioid use disorder (OUD). This medication helps to suppress withdrawal symptoms and reduce cravings, aiding patients in their recovery journey. However, the high cost of brand-name Suboxone has led to the development and use of generic versions, which are intended to be more affordable alternatives .
Patient Experiences with Generic Buprenorphine/Naloxone
Withdrawal Symptoms and Preferences
Research indicates that some patients experience differences in the suppression of withdrawal symptoms when switched from brand-name Suboxone to generic versions. A study involving 24 OUD patients who were switched to generic formulations manufactured by Sandoz or Alvogen found that 37.5% of these patients reported withdrawal symptoms, cravings, and other adverse effects such as insomnia, muscle pain, and gooseflesh skin . These patients expressed a preference for the brand-name formulation over the generics, highlighting the need for careful monitoring and potential dose adjustments when making such switches .
Clinical Case Study Insights
A case study of a 56-year-old patient who was switched from Suboxone to generic formulations also reported withdrawal symptoms and a positive toxicology screen for fentanyl during the transition period. The study noted that the generic formulations had higher exposure levels than the brand-name drug, suggesting that the pharmacokinetics of the generics might differ from Suboxone. This case underscores the importance of monitoring patients closely and adjusting doses as necessary to maintain treatment efficacy .
Economic and Policy Implications
Cost and Access to Treatment
The high cost of brand-name Suboxone has been a barrier to treatment for many patients. Anti-competitive practices by brand firms have extended exclusivity periods and delayed the entry of generic alternatives, keeping prices high. Policy changes, such as the proposed CREATES Act and modernization of the Hatch-Waxman Act, aim to address these issues and facilitate generic competition. Such measures could lead to significant cost savings, with estimates suggesting potential savings of approximately $703 million overall and $203 million to Medicaid in 2017 alone .
Prescription Patterns and Clinical Conditions
Trends in Buprenorphine/Naloxone Prescriptions
An analysis of prescription claims data from Massachusetts revealed a substantial increase in the number of patients prescribed buprenorphine/naloxone, from 25,000 in 2011 to over 39,000 in 2015. While the primary indication for these prescriptions was opioid use disorder, a notable percentage of prescriptions were also associated with pain-related conditions. This suggests that clinicians may be prescribing buprenorphine/naloxone not only for OUD but also for pain management, particularly in patients at elevated risk for opioid use disorder .
Conclusion
The transition from brand-name Suboxone to generic buprenorphine/naloxone formulations presents both challenges and opportunities. While generics offer a more affordable option, patient experiences indicate that withdrawal symptoms and other adverse effects may occur, necessitating careful monitoring and dose adjustments. Policy changes to promote generic competition could significantly reduce costs and improve access to treatment. Understanding prescription patterns and associated clinical conditions can further inform best practices in the use of buprenorphine/naloxone for both OUD and pain management.
Sources and full results
Most relevant research papers on this topic